| Clinical data | |
|---|---|
| Other names | 1,3-benzodioxolyl-N-methyl-5-ethanamine; 3,4-methylenedioxy-N-methyl-2-phenylethylamine; Norlobivine |
| Routes of administration | Various |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H13NO2 |
| Molar mass | 179.219 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Homarylamine (INN;[1] also known as3,4-methylenedioxy-N-methylphenethylamine andMDMPEA) is anantitussive (anti-cough) drug[2] which was patented in 1956 byMerck & Co.,[3] but has never been used medically as such.
Chemically it is asubstituted phenethylamine. It is theN-methylatedanalog ofmethylenedioxyphenethylamine (MDPEA). It is a schedule I drug in the USA as a positional isomer of MDA.
Reaction of homoarylamine withformaldehyde giveshydrastinine.
A practical application of homarylamine is in the synthesis ofRoemerin [de].[4]
Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |